Definition of Tislelizumab. Meaning of Tislelizumab. Synonyms of Tislelizumab

Here you will find one or more explanations in English for the word Tislelizumab. Also in the bottom left of the page several parts of wikipedia pages related to the word Tislelizumab and, of course, Tislelizumab synonyms and on the right images related to the word Tislelizumab.

Definition of Tislelizumab

No result for Tislelizumab. Showing similar results...

Meaning of Tislelizumab from wikipedia

- Tislelizumab, sold under the brand name Tevimbra among others, is a humanized monoclonal antibody directed against programmed death receptor-1. It is being...
- medicines is tislelizumab (BGB-A317), a PD-1 antibody or PD-L1 inhibitor that prevents cancer tumors from evading the immune system. Tislelizumab is being...
- B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion...
- (INN) tirzepatide (INN) Tis-U-Sol tisagenlecleucel (INN) Tiseb Tisit tislelizumab (INN) tisocalcitate (USAN) tisocromide (INN) tisopurine (INN) tisoquone...
- Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab L01FF11 Sugemalimab L01FF12 Serplulimab L01FF13...
- govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...
- human AOC3 tiragolumab mab human Tiragotumab mab human TIGIT cancer Tislelizumab mab humanized PCDC1, CD279 non-small cell lung cancer Tisotumab vedotin...
- and Eli Lilly for patients with non-small cell lung cancer (NSCLC). Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody in pivotal...
- Satralizumab Siplizumab Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab...
- govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zolbetuximab...